The Complete GLP-1 Guide UK 2026

What are GLP-1 receptor agonists?

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic the action of glucagon-like peptide-1, a hormone naturally produced in the gut after eating. This hormone plays a central role in appetite regulation, blood sugar control and metabolic health.

Originally developed for type 2 diabetes in the early 2000s, GLP-1 RAs have since been recognised as one of the most effective pharmaceutical treatments for obesity. In the UK, they are now prescribed for both diabetes and chronic weight management under NHS and private pathways.

The medications work by binding to GLP-1 receptors in the brain, pancreas and gut, producing several coordinated effects: they reduce appetite, slow gastric emptying, improve insulin secretion and may reduce inflammation throughout the body. Newer dual-receptor agonists like tirzepatide also target the GIP receptor, producing even greater weight loss.

GLP-1 medications available in the UK

Several GLP-1 receptor agonists are licensed and available in the United Kingdom. Each has distinct indications, dosing schedules and NHS funding arrangements.

The newest addition to the UK market is Mounjaro (tirzepatide), which received NICE approval in 2024 and has been rolling out across NHS specialist services. Unlike semaglutide, tirzepatide targets both GLP-1 and GIP receptors, a mechanism known as dual incretin agonism.

How GLP-1 drugs work

Understanding how semaglutide works helps explain why these medications are so effective. GLP-1 receptor agonists produce their effects through multiple coordinated pathways:

• Appetite suppression: GLP-1 RAs act on hypothalamic receptors to reduce hunger signals and increase satiety, making patients feel full sooner and for longer.
• Delayed gastric emptying: Food moves more slowly through the stomach, prolonging the feeling of fullness after meals.
• Improved insulin signalling: They enhance glucose-dependent insulin secretion whilst suppressing glucagon, improving blood sugar control without causing hypoglycaemia when used alone.
• Reduced food reward: Brain imaging studies suggest GLP-1 RAs reduce the reward value of highly palatable foods, helping patients make healthier dietary choices.
• Anti-inflammatory effects: Emerging evidence shows direct anti-inflammatory properties that may contribute to cardiovascular and metabolic benefits.

Getting GLP-1 medication on the NHS

NHS access to GLP-1 medications for weight management follows NICE technology appraisal guidance. The pathway typically involves referral through a specialist weight management service (Tier 3).

Eligibility criteria (NICE TA)

• BMI of 35 kg/m² or above, or
• BMI of 30–34.9 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea, cardiovascular disease)
• BMI thresholds are adjusted 2.5 kg/m² lower for South Asian, Chinese and Black African/Caribbean ethnic groups
• Previous engagement with lifestyle interventions

For detailed NHS pathways, see our guides on how to get Wegovy on the NHS and Mounjaro NHS access in 2026.

Private prescription options

Many UK patients access GLP-1 medications through private prescriptions, either from high-street pharmacies or regulated online clinics. This pathway avoids NHS waiting lists but comes with significant monthly costs.

When considering private options, it is essential to use MHRA-registered pharmacies and GPhC-registered prescribers. Our guide to buying Ozempic online safely in the UK covers the key safety checks. You can also explore NHS and private weight loss clinics across the UK and structured weight loss programmes.

Side effects and safety

All GLP-1 medications share a common side effect profile, predominantly gastrointestinal. Most side effects are mild to moderate and improve within the first 4–8 weeks of treatment as the dose is gradually titrated.

Common side effects

For a comprehensive breakdown, see our dedicated guide on GLP-1 side effects and Ozempic-specific side effects in the UK.

• Nausea (30–44% of patients, usually resolves within weeks)
• Vomiting, diarrhoea and constipation
• Abdominal pain and bloating
• Injection site reactions
• Headache and fatigue

Less common but important concerns

• Hair loss (telogen effluvium) — temporary, related to rapid weight loss
• Facial volume loss ("Ozempic face") — visible facial ageing from fat loss
• Muscle loss — mitigated with protein intake and resistance training
• Thyroid concerns — precautionary contraindication for MTC/MEN2
• Cancer risk considerations — current evidence reassuring

Alcohol and drug interactions

Patients frequently ask about combining GLP-1 RAs with alcohol. Our guide on Ozempic and alcohol covers the evidence on altered alcohol tolerance, increased nausea risk and liver considerations.

Weight loss expectations

GLP-1 receptor agonists produce significantly greater weight loss than previous anti-obesity medications or lifestyle interventions alone.

It is crucial to understand that weight management with GLP-1 RAs is a long-term commitment. Our guide on what happens when you stop Ozempic explains the evidence on weight regain, which averages two-thirds of lost weight within a year of discontinuation.

Diet, exercise and lifestyle

GLP-1 medications work best when combined with structured lifestyle changes. Clinical trials consistently show that patients who adopt dietary modifications and increase physical activity alongside medication achieve superior, more sustainable results.

Key lifestyle recommendations include consuming 1.2–1.6 g of protein per kilogram of body weight daily to preserve lean mass, engaging in at least 150 minutes of moderate-intensity exercise per week (including resistance training twice weekly), staying well hydrated and eating slowly to reduce nausea.

Medication comparisons

Choosing between GLP-1 medications depends on individual circumstances, including the primary treatment goal, NHS availability, cost tolerance and medical history.

For patients with type 2 diabetes, the choice also depends on glycaemic control targets and existing medications. See our guide on GLP-1 for type 2 diabetes in the UK.

GLP-1 and specific health conditions

Beyond weight loss and diabetes, GLP-1 RAs are being studied for a remarkable range of health conditions. Evidence is strongest for cardiovascular benefit and is growing rapidly for liver disease, kidney protection and more.

Cardiovascular health

The landmark SELECT trial demonstrated that semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with obesity and established heart disease. This led to NICE approval for cardiovascular risk reduction in 2026. GLP-1 RAs also improve cholesterol profiles, lowering triglycerides and LDL cholesterol.

Liver and metabolic health

GLP-1 RAs show significant benefit for non-alcoholic fatty liver disease (NAFLD/MASLD), reducing liver fat, inflammation and fibrosis. Our guide on GLP-1 and fatty liver disease covers the ESSENCE trial and current NICE guidance.

Kidney protection

The FLOW trial demonstrated that semaglutide slows the progression of chronic kidney disease in patients with type 2 diabetes. Read more in our GLP-1 and kidney disease guide.

Sleep apnoea

Weight loss from GLP-1 RAs can significantly reduce the severity of obstructive sleep apnoea. The SURMOUNT-OSA trial showed clinically meaningful improvements in AHI scores. See GLP-1 and sleep apnoea.

Joint health

Weight reduction from GLP-1 treatment offers significant benefits for osteoarthritis and joint pain. Every kilogram lost reduces knee joint load by approximately four kilograms. See GLP-1 and joint health.

Mental health

The relationship between GLP-1 RAs and mental health is complex. Improved body image and physical health can boost wellbeing, though some patients report mood changes. Our guide on GLP-1 and mental health covers the evidence on depression, anxiety and suicidality screening.

Inflammation

GLP-1 RAs demonstrate direct anti-inflammatory effects beyond what weight loss alone would produce, with reductions in CRP, IL-6 and TNF-alpha. Read more at GLP-1 and inflammation.

Prediabetes and prevention

For the estimated 13.6 million UK adults with prediabetes, GLP-1 RAs can prevent progression to type 2 diabetes. Our GLP-1 and prediabetes guide covers the evidence and access pathways.

Special populations

GLP-1 treatment considerations vary significantly for certain patient groups. Always discuss your individual circumstances with your prescriber.

Older adults require particular attention to muscle and bone preservation. Teenagers may be eligible for Wegovy from age 12 under specialist supervision. Women planning pregnancy should discontinue GLP-1 RAs at least two months before conception, though the medications may improve fertility in women with obesity-related anovulation.

Cost and affordability

The cost of GLP-1 medications remains a significant consideration for UK patients, particularly those unable to access NHS prescriptions.

For a comprehensive pricing analysis, see GLP-1 prices: UK vs Europe comparison. Generic semaglutide may reach the UK market in coming years — our Ozempic generic UK guide tracks the latest developments.

Practical guidance

Starting GLP-1 treatment involves several practical considerations beyond the medication itself.

Injection technique

All current GLP-1 RAs for weight management are administered via subcutaneous injection using a pre-filled pen. Our step-by-step guide on how to inject Ozempic covers site selection, rotation, storage and disposal.

Oral options

For patients who prefer not to inject, oral semaglutide (Rybelsus) is available for type 2 diabetes. Higher-dose oral formulations for weight management are in late-stage development.

Stopping treatment

Understanding what happens when you stop GLP-1 medication is essential for long-term planning. Weight regain is the norm, which is why current guidance recommends ongoing treatment for chronic weight management.

The future of GLP-1 treatments

The GLP-1 field is evolving rapidly. Several developments are expected to reshape the UK treatment landscape over the coming years. Our guide to future weight loss treatments covers the full pipeline.

• Oral GLP-1 for obesity: Higher-dose oral semaglutide (50 mg daily) achieved 17.4% weight loss in the OASIS-1 trial and may receive MHRA approval by 2027.
• CagriSema: Novo Nordisk's combination of semaglutide and cagrilintide achieved 22.7% weight loss, rivalling tirzepatide.
• Survodutide: A dual GLP-1/glucagon agonist showing 18–19% weight loss with particular benefits for fatty liver disease.
• Retatrutide: A triple-agonist targeting GLP-1, GIP and glucagon receptors, achieving up to 24% weight loss in phase 2 trials.
• Generic semaglutide: Patent expiry may bring affordable alternatives to UK patients within the next few years.

The broader obesity treatment landscape in the UK is also shifting, with increased NHS commissioning, specialist services expansion and potential integration of GLP-1 RAs into primary care.

Frequently asked questions

What are GLP-1 receptor agonists?

GLP-1 receptor agonists are injectable (and oral) medications that mimic the gut hormone GLP-1. They reduce appetite, slow gastric emptying and improve blood sugar control. In the UK, the main options are semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro). See our complete FAQ page for 30 more answers.

Can I get GLP-1 medication on the NHS?

Yes, if you meet NICE eligibility criteria: typically BMI 35+ or BMI 30+ with comorbidities. Access is through specialist weight management services. Waiting times vary regionally. See how to get Wegovy on the NHS.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide. Ozempic is licensed for type 2 diabetes (up to 2 mg). Wegovy is licensed for weight management at the higher 2.4 mg dose. See our detailed Ozempic vs Wegovy comparison.

How much weight can I expect to lose?

Average weight loss ranges from 15% (semaglutide 2.4 mg) to 22.5% (tirzepatide 15 mg) of body weight over 12–18 months. Individual results vary. Combining medication with lifestyle changes produces the best outcomes.

Are GLP-1 injections safe long-term?

Semaglutide has over 8 years of post-marketing safety data. The most common side effects are gastrointestinal (nausea, vomiting) and typically resolve within weeks. Serious adverse events are rare. Long-term cardiovascular safety is confirmed by the SELECT trial. See our comprehensive side effects guide.

Sources

• NICE — Technology Appraisals: Semaglutide (TA875), Tirzepatide (TA1026) for weight management
• NICE — Semaglutide for cardiovascular risk reduction (TA1064)
• MHRA — Summary of Product Characteristics: Wegovy, Ozempic, Mounjaro, Saxenda, Rybelsus
• BNF — Semaglutide, Tirzepatide, Liraglutide monographs (bnf.nice.org.uk)
• Wilding JPH et al. STEP 1. N Engl J Med 2021; 384:989–1002
• Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022; 387:205–216
• Lincoff AM et al. SELECT. N Engl J Med 2023; 389:2221–2232
• Perkovic V et al. FLOW. N Engl J Med 2024; 391:109–121
• NHS England — Specialist weight management services commissioning guidance
• Diabetes UK — GLP-1 receptor agonists position statement